CAMP4 is currently working on CMP-CPS-001, a novel investigational therapy designed to address the underlying cause of UCDs by regulating genes associated with the condition. The first clinical trial of this program was initiated in March 2024 with a phase 1 single-ascending dose study in healthy volunteers. Following the completion of this trial, a multiple-ascending dose study was initiated.